Dr. Jennifer Bath, CEO & President of ImmunoPrecise Antibodies Ltd. IPA was recently interviewed by Biedex Markets.
ImmunoPrecise is a biotherapeutic research company and is a leader in antibody discovery services, utilizing complex artificial intelligence technologies. The company integrates cutting-edge tech and AI in its propriety platform, LENSai.
The revolutionary technology pools together data and disparate knowledge across scientific literature – knowledge that may have been previously siloed – to make insights that would not be possible otherwise.
Watch the full interview here:
Featured photo by Moritz Kindler on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Biedex Markets.com. Biedex Markets does not provide investment advice. All rights reserved.
